QSAM Biosciences, Inc. A408WA

A408WA Company Overview

QSAM Biosciences, Inc. is a clinical-stage biotechnology and radiopharmaceutical company focused on the development of targeted therapeutic and diagnostic products for cancer and related diseases. The company primarily operates in the oncology and nuclear medicine sectors, with an emphasis on radiopharmaceutical therapies designed to deliver targeted radiation to metastatic and primary bone cancer lesions. Its core development program is CycloSam®, a radiotherapeutic candidate based on Samarium-153 linked with DOTMP technology for the treatment of bone cancer and bone marrow ablation applications.

The company’s primary strategic focus is advancing clinical development, regulatory engagement, and commercialization planning for its radiopharmaceutical platform. QSAM Biosciences evolved from earlier-stage biotechnology operations and repositioned its business around nuclear medicine and targeted radiotherapy technologies. Public disclosures and company filings indicate that its business model is centered on intellectual property development, clinical trials, licensing opportunities, and potential strategic collaborations within the oncology therapeutics market.